Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2+GMCSF vs. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with operable breast cancer.

被引：6

作者：

Patel, Snehal ^{[1
]}

McWilliams, David ^{[1
]}

Fischette, Christine T. ^{[1
]}

Thompson, Jaye ^{[1
]}

Patel, Mira ^{[1
]}

Daugherty, F. Joseph ^{[1
]}

机构：

[1] Greenwich LifeSci, Stafford, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.542

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

542

引用

页数：3

共 13 条

[1] Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2+GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer
Patel, Snehal S.
McWilliams, David B.
Patel, Marisa S.
Fischette, Christine T.
Thompson, Jaye
Daugherty, F. Joseph
CANCER RESEARCH, 2021, 81 (04)
[2] Final five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating a time series of immune responses using HER2/neu peptide GP2+GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer.
Patel, Snehal S.
McWilliams, David B.
Patel, Mira S.
Fischette, Christine T.
Thompson, Jaye
Daugherty, F. Joseph
CANCER RESEARCH, 2021, 81 (13)
[3] Analysis of GP2 immune response and relationship to recurrence in a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2 (GLSI-100) vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer
Patel, Snehal S.
McWilliams, David B.
Patel, Mira S.
Fischette, Christine T.
Thompson, Jaye
Daugherty, F. Joseph
CANCER RESEARCH, 2022, 82 (04)
[4] A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2+GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.
Patel, Snehal
McWilliams, David
Fischette, Christine T.
Thompson, Jaye
Daugherty, F. Joseph
Osborne, C. Kent
Rimawi, Mothaffar F.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2+GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.
Patel, Snehal S.
McWilliams, David B.
Fischette, Christine T.
Thompson, Jaye
Daugherty, F. Joseph
Osborne, C. Kent
Rimawi, Mothaffar F.
CANCER RESEARCH, 2021, 81 (13)
[6] Evaluation of booster injections in maintaining peak immunity in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) versus GM-CSF alone after adjuvant trastuzumab in women with HER2-positive breast cancer.
Patel, Snehal
McWilliams, David
Thompson, Jaye
Patel, Mira
Daugherty, F. Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[7] Baseline GP2 immune response as an independent prognostic factor in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) versus. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with breast cancer.
Patel, Snehal
McWilliams, David
Thompson, Jaye
Patel, Mira
Daugherty, F. Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neupeptide GP2+GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer
Patel, Snehal S.
McWilliams, David B.
Fischette, Christine T.
Thompson, Jaye
Daugherty, F. Joseph
Osborne, C. Kent
Rimawi, Mothaffar F.
CANCER RESEARCH, 2021, 81 (04)
[9] Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial.
Hickerson, Annelies
Clifton, G. Travis
Hale, Diane F.
Peace, Kaitlin M.
Holmes, Jarrod P.
Vreeland, Timothy J.
Litton, Jennifer Keating
Murthy, Rashmi Krishna
Lukas, Jason Jerome
Mittendorf, Elizabeth A.
Earl, George
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[10] A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2+GM-CSF) in patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy
Patel, Snehal S.
McWilliams, David B.
Fischette, Christine T.
Thompson, Jaye
Daugherty, F. Joseph
Osborne, C. Kent
Rimawi, Mothaffar F.
CANCER RESEARCH, 2022, 82 (04)

← 1 2 →